A multi-component DE-implementation intervention to reduce inappropriate VTE prophylaxis among hospitalized patients
Active Grant Awarded Last action
- Award ID
- R01HL183351
- Recipient
-
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University UEI M5QFLTCTSQN6
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,370,372
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 4% complete
- Place of performance
- Cleveland, OH 44195, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $2,370,372 on September 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds grant R01HL183351, a multi-component de-implementation intervention called AVERT that aims to reduce inappropriate venous thromboembolism (VTE) prophylaxis among hospitalized patients. The intervention combines automated patient risk assessments integrated into the EMR, personalized treatment recommendations, and audit and feedback of prescribing performance. The recipient will test it through a stepped-wedge cluster-randomized trial across 24 acute care hospitals within 7 health systems, reaching approximately 250,000 patients, using a hybrid Type II design that simultaneously evaluates implementation effectiveness and clinical outcomes. The intervention seeks to reduce non-evidence-based heparin prescribing and lower adverse drug events such as bleeding and heparin-induced thrombocytopenia without increasing hospital-acquired VTE. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of May 31, 2031. Place of performance is Cleveland, OH 44195.
Description
- Abstract
- Venous thromboembolism (VTE, which includes deep vein thrombosis and pulmonary embolism), is a preventable cause of morbidity and mortality in hospitalized patients. VTE affects nearly 1% of medical inpatients and significantly increases hospital stays and costs. National quality improvement initiatives have increased the use of pharmacologic prophylaxis for VTE. Unfortunately, this has also led to overuse of prophylaxis among patients at low risk for VTE and those at high risk for bleeding, resulting in unnecessary patient harm and waste. To address this, the avert intervention seeks to optimize prescribing practices through a multi-component DE-implementation strategy that includes automated patient risk assessments integrated into the EMR, personalized treatment recommendations, and audit and feedback of performance. By providing clinicians with clear, patient-specific information about VTE and bleeding risks, along with guideline-based recommendations, we aim to overcome barriers to optimal prescribing, such as uncertainty about a patient's risk for VTE or bleeding and concerns about adverse outcomes from withholding prophylaxis. Building on implementation science frameworks, preliminary qualitative research with hospitalists, and data from a prior trial, avert should reduce non-evidence-based prescribing of heparins, while lowering the risk of adverse drug events like bleeding and heparin-induced thrombocytopenia (HIT), without increasing the risk of hospital-acquired VTE. To test our approach, we will conduct a stepped-wedge cluster-randomized trial across 24 acute care hospitals within 7 health systems, reaching approximately 250,000 patients. The trial uses a hybrid type II design to simultaneously evaluate the effectiveness of the DE-implementation strategy while assessing clinical outcomes. Using an explanatory sequential mixed-methods approach we will explore the organizational and contextual factors that influence successful implementation and sustainability. If successful, the avert intervention will provide robust evidence to improve the quality of care and avoid unnecessary (and potentially harmful) care for millions of hospitalized adults annually.
Quick answers
Who received award R01HL183351?
R01HL183351 was awarded to Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R01HL183351 worth?
$2,370,372 has been obligated on R01HL183351.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award